Bailard’s Minerva Neurosciences NERV Stock Holding History

Bailard’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,050	Closed	-$20K	–	757
2022 Q1	$20K	Buy	+3,050	New	+$18.7K	﹤0.01%	715

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bailard's NERV Position: Q2 2022 in Review

Bailard sold out of Minerva Neurosciences (NERV) in Q2 2022, closing a stake of 3,050 shares — an estimated $20K sold.

Bailard first reported a position in NERV in Q1 2022 and held it in 1 quarter. The position peaked at $20K in Q1 2022. 23 funds tracked by Wall St. Rank hold NERV as of Q2 2022.

Bailard reported no remaining Minerva Neurosciences position as of Q2 2022 after selling out during the quarter.
Bailard sold 3,050 Minerva Neurosciences shares in Q2 2022, an estimated $20K.
Bailard first reported a position in Minerva Neurosciences in Q1 2022 and held it in 1 quarter.
Bailard's Minerva Neurosciences position peaked at $20K in Q1 2022.
23 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.